nodes	percent_of_prediction	percent_of_DWPC	metapath
Famotidine—SLC47A1—Metformin—polycystic ovary syndrome	0.674	0.764	CbGbCtD
Famotidine—SLC22A2—Metformin—polycystic ovary syndrome	0.209	0.236	CbGbCtD
Famotidine—SLC22A8—urine—polycystic ovary syndrome	0.00581	0.194	CbGeAlD
Famotidine—CYP2C19—urine—polycystic ovary syndrome	0.00487	0.163	CbGeAlD
Famotidine—Appetite absent—Metformin—polycystic ovary syndrome	0.00346	0.103	CcSEcCtD
Famotidine—SLC47A1—adrenal cortex—polycystic ovary syndrome	0.00201	0.067	CbGeAlD
Famotidine—HRH2—adrenal gland—polycystic ovary syndrome	0.00188	0.0627	CbGeAlD
Famotidine—SLC47A1—endometrium—polycystic ovary syndrome	0.00179	0.0598	CbGeAlD
Famotidine—SLC47A1—uterus—polycystic ovary syndrome	0.00165	0.0551	CbGeAlD
Famotidine—HRH2—endocrine gland—polycystic ovary syndrome	0.00163	0.0543	CbGeAlD
Famotidine—SLC47A1—pituitary gland—polycystic ovary syndrome	0.00162	0.0541	CbGeAlD
Famotidine—SLC47A1—adipose tissue—polycystic ovary syndrome	0.00161	0.0539	CbGeAlD
Famotidine—Ear pain—Metformin—polycystic ovary syndrome	0.00147	0.0434	CcSEcCtD
Famotidine—SLC47A1—adrenal gland—polycystic ovary syndrome	0.00145	0.0484	CbGeAlD
Famotidine—Nasal congestion—Metformin—polycystic ovary syndrome	0.00137	0.0407	CcSEcCtD
Famotidine—SLC47A1—female gonad—polycystic ovary syndrome	0.00135	0.0451	CbGeAlD
Famotidine—SLC47A1—vagina—polycystic ovary syndrome	0.00134	0.0448	CbGeAlD
Famotidine—SLC47A1—endocrine gland—polycystic ovary syndrome	0.00126	0.0419	CbGeAlD
Famotidine—Pain in extremity—Metformin—polycystic ovary syndrome	0.00125	0.0371	CcSEcCtD
Famotidine—Migraine—Metformin—polycystic ovary syndrome	0.00123	0.0365	CcSEcCtD
Famotidine—Cramp muscle—Metformin—polycystic ovary syndrome	0.00113	0.0334	CcSEcCtD
Famotidine—Influenza—Metformin—polycystic ovary syndrome	0.00108	0.032	CcSEcCtD
Famotidine—Abdominal discomfort—Metformin—polycystic ovary syndrome	0.00104	0.0307	CcSEcCtD
Famotidine—Neutropenia—Metformin—polycystic ovary syndrome	0.00101	0.03	CcSEcCtD
Famotidine—Upper respiratory tract infection—Metformin—polycystic ovary syndrome	0.001	0.0298	CcSEcCtD
Famotidine—Bradycardia—Metformin—polycystic ovary syndrome	0.000881	0.0261	CcSEcCtD
Famotidine—Hepatitis—Metformin—polycystic ovary syndrome	0.000865	0.0256	CcSEcCtD
Famotidine—CYP2C19—vagina—polycystic ovary syndrome	0.000863	0.0288	CbGeAlD
Famotidine—CYP2C19—endocrine gland—polycystic ovary syndrome	0.000808	0.027	CbGeAlD
Famotidine—Flushing—Metformin—polycystic ovary syndrome	0.000803	0.0238	CcSEcCtD
Famotidine—Dysgeusia—Metformin—polycystic ovary syndrome	0.000738	0.0219	CcSEcCtD
Famotidine—Muscle spasms—Metformin—polycystic ovary syndrome	0.000724	0.0215	CcSEcCtD
Famotidine—Syncope—Metformin—polycystic ovary syndrome	0.000676	0.02	CcSEcCtD
Famotidine—Palpitations—Metformin—polycystic ovary syndrome	0.000666	0.0197	CcSEcCtD
Famotidine—Loss of consciousness—Metformin—polycystic ovary syndrome	0.000662	0.0196	CcSEcCtD
Famotidine—Myalgia—Metformin—polycystic ovary syndrome	0.000641	0.019	CcSEcCtD
Famotidine—Chest pain—Metformin—polycystic ovary syndrome	0.000641	0.019	CcSEcCtD
Famotidine—Oedema—Metformin—polycystic ovary syndrome	0.000615	0.0182	CcSEcCtD
Famotidine—Infection—Metformin—polycystic ovary syndrome	0.000611	0.0181	CcSEcCtD
Famotidine—Shock—Metformin—polycystic ovary syndrome	0.000605	0.0179	CcSEcCtD
Famotidine—Thrombocytopenia—Metformin—polycystic ovary syndrome	0.000602	0.0178	CcSEcCtD
Famotidine—Anorexia—Metformin—polycystic ovary syndrome	0.000586	0.0174	CcSEcCtD
Famotidine—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.00056	0.0166	CcSEcCtD
Famotidine—Paraesthesia—Metformin—polycystic ovary syndrome	0.000552	0.0164	CcSEcCtD
Famotidine—Somnolence—Metformin—polycystic ovary syndrome	0.000547	0.0162	CcSEcCtD
Famotidine—Dyspepsia—Metformin—polycystic ovary syndrome	0.000541	0.016	CcSEcCtD
Famotidine—Decreased appetite—Metformin—polycystic ovary syndrome	0.000534	0.0158	CcSEcCtD
Famotidine—Fatigue—Metformin—polycystic ovary syndrome	0.00053	0.0157	CcSEcCtD
Famotidine—Constipation—Metformin—polycystic ovary syndrome	0.000526	0.0156	CcSEcCtD
Famotidine—Feeling abnormal—Metformin—polycystic ovary syndrome	0.000507	0.015	CcSEcCtD
Famotidine—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.000503	0.0149	CcSEcCtD
Famotidine—Urticaria—Metformin—polycystic ovary syndrome	0.000488	0.0145	CcSEcCtD
Famotidine—Abdominal pain—Metformin—polycystic ovary syndrome	0.000486	0.0144	CcSEcCtD
Famotidine—Asthenia—Metformin—polycystic ovary syndrome	0.000441	0.0131	CcSEcCtD
Famotidine—Pruritus—Metformin—polycystic ovary syndrome	0.000435	0.0129	CcSEcCtD
Famotidine—Diarrhoea—Metformin—polycystic ovary syndrome	0.000421	0.0125	CcSEcCtD
Famotidine—Dizziness—Metformin—polycystic ovary syndrome	0.000407	0.012	CcSEcCtD
Famotidine—Vomiting—Metformin—polycystic ovary syndrome	0.000391	0.0116	CcSEcCtD
Famotidine—Rash—Metformin—polycystic ovary syndrome	0.000388	0.0115	CcSEcCtD
Famotidine—Dermatitis—Metformin—polycystic ovary syndrome	0.000387	0.0115	CcSEcCtD
Famotidine—Headache—Metformin—polycystic ovary syndrome	0.000385	0.0114	CcSEcCtD
Famotidine—Nausea—Metformin—polycystic ovary syndrome	0.000365	0.0108	CcSEcCtD
Famotidine—HRH2—Class A/1 (Rhodopsin-like receptors)—ADRA1A—polycystic ovary syndrome	0.000259	0.00485	CbGpPWpGaD
Famotidine—HRH2—GPCRs, Class A Rhodopsin-like—MTNR1B—polycystic ovary syndrome	0.000257	0.00481	CbGpPWpGaD
Famotidine—HRH2—Class A/1 (Rhodopsin-like receptors)—ADRB3—polycystic ovary syndrome	0.00025	0.00467	CbGpPWpGaD
Famotidine—HRH2—Class A/1 (Rhodopsin-like receptors)—LHB—polycystic ovary syndrome	0.000247	0.00461	CbGpPWpGaD
Famotidine—CYP2C19—Arachidonic acid metabolism—AKR1C3—polycystic ovary syndrome	0.000247	0.00461	CbGpPWpGaD
Famotidine—HRH2—Class A/1 (Rhodopsin-like receptors)—GNRH1—polycystic ovary syndrome	0.000241	0.00451	CbGpPWpGaD
Famotidine—CYP2C19—Melatonin metabolism and effects—CYP1A1—polycystic ovary syndrome	0.000239	0.00448	CbGpPWpGaD
Famotidine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP11A1—polycystic ovary syndrome	0.000226	0.00422	CbGpPWpGaD
Famotidine—CYP2C19—Oxidation by Cytochrome P450—CYP11A1—polycystic ovary syndrome	0.000223	0.00416	CbGpPWpGaD
Famotidine—SLC22A8—Transmembrane transport of small molecules—TRPV6—polycystic ovary syndrome	0.000222	0.00415	CbGpPWpGaD
Famotidine—HRH2—Class A/1 (Rhodopsin-like receptors)—MTNR1B—polycystic ovary syndrome	0.000221	0.00412	CbGpPWpGaD
Famotidine—SLC22A2—Transmembrane transport of small molecules—ABCB6—polycystic ovary syndrome	0.000217	0.00406	CbGpPWpGaD
Famotidine—HRH2—GPCR ligand binding—FSHR—polycystic ovary syndrome	0.000216	0.00404	CbGpPWpGaD
Famotidine—SLC22A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A4—polycystic ovary syndrome	0.000215	0.00402	CbGpPWpGaD
Famotidine—CYP2C19—Metapathway biotransformation—AKR1C2—polycystic ovary syndrome	0.000211	0.00395	CbGpPWpGaD
Famotidine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP17A1—polycystic ovary syndrome	0.00021	0.00392	CbGpPWpGaD
Famotidine—CYP2C19—Oxidation by Cytochrome P450—CYP17A1—polycystic ovary syndrome	0.000207	0.00387	CbGpPWpGaD
Famotidine—SLC22A8—Transmembrane transport of small molecules—SCNN1A—polycystic ovary syndrome	0.000201	0.00376	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—NPB—polycystic ovary syndrome	0.0002	0.00374	CbGpPWpGaD
Famotidine—HRH2—GPCR ligand binding—ADRA1A—polycystic ovary syndrome	0.000198	0.00369	CbGpPWpGaD
Famotidine—HRH2—GPCR ligand binding—ADRB3—polycystic ovary syndrome	0.00019	0.00355	CbGpPWpGaD
Famotidine—HRH2—GPCR ligand binding—LHB—polycystic ovary syndrome	0.000188	0.00351	CbGpPWpGaD
Famotidine—HRH2—GPCR ligand binding—GNRH1—polycystic ovary syndrome	0.000184	0.00343	CbGpPWpGaD
Famotidine—CYP2C19—Phase 1 - Functionalization of compounds—CYP11A1—polycystic ovary syndrome	0.000183	0.00342	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—NPB—polycystic ovary syndrome	0.000181	0.00339	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—PLEKHG5—polycystic ovary syndrome	0.000181	0.00338	CbGpPWpGaD
Famotidine—SLC47A1—Transmembrane transport of small molecules—TFRC—polycystic ovary syndrome	0.000178	0.00333	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—ARHGAP23—polycystic ovary syndrome	0.000177	0.00331	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—ARHGAP30—polycystic ovary syndrome	0.000177	0.00331	CbGpPWpGaD
Famotidine—HRH2—G alpha (s) signalling events—POMC—polycystic ovary syndrome	0.000177	0.0033	CbGpPWpGaD
Famotidine—HRH2—GPCR ligand binding—SCT—polycystic ovary syndrome	0.000176	0.00329	CbGpPWpGaD
Famotidine—CYP2C19—Phase 1 - Functionalization of compounds—CYP17A1—polycystic ovary syndrome	0.00017	0.00318	CbGpPWpGaD
Famotidine—HRH2—GPCR ligand binding—MTNR1B—polycystic ovary syndrome	0.000168	0.00314	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—PTGER3—polycystic ovary syndrome	0.000167	0.00312	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—LHCGR—polycystic ovary syndrome	0.000167	0.00312	CbGpPWpGaD
Famotidine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP19A1—polycystic ovary syndrome	0.000166	0.0031	CbGpPWpGaD
Famotidine—SLC47A1—Transmembrane transport of small molecules—PLAT—polycystic ovary syndrome	0.000165	0.00309	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—PLEKHG5—polycystic ovary syndrome	0.000164	0.00307	CbGpPWpGaD
Famotidine—CYP2C19—Oxidation by Cytochrome P450—CYP19A1—polycystic ovary syndrome	0.000164	0.00306	CbGpPWpGaD
Famotidine—HRH2—Class A/1 (Rhodopsin-like receptors)—GHRL—polycystic ovary syndrome	0.000163	0.00305	CbGpPWpGaD
Famotidine—HRH2—GPCRs, Class A Rhodopsin-like—ADRB2—polycystic ovary syndrome	0.000157	0.00294	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—PTAFR—polycystic ovary syndrome	0.000156	0.00292	CbGpPWpGaD
Famotidine—CYP2C19—Arachidonic acid metabolism—CYP1A1—polycystic ovary syndrome	0.000155	0.00289	CbGpPWpGaD
Famotidine—SLC22A2—Transmembrane transport of small molecules—TRPV6—polycystic ovary syndrome	0.000155	0.00289	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—LHCGR—polycystic ovary syndrome	0.000151	0.00283	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—PTGER3—polycystic ovary syndrome	0.000151	0.00283	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—ADRA1D—polycystic ovary syndrome	0.000151	0.00283	CbGpPWpGaD
Famotidine—SLC47A1—Transmembrane transport of small molecules—SLC2A4—polycystic ovary syndrome	0.000151	0.00283	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—ADRA1B—polycystic ovary syndrome	0.000147	0.00275	CbGpPWpGaD
Famotidine—SLC22A2—Transmission across Chemical Synapses—CAMK2D—polycystic ovary syndrome	0.000145	0.00272	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—PTAFR—polycystic ovary syndrome	0.000142	0.00265	CbGpPWpGaD
Famotidine—SLC22A8—SLC-mediated transmembrane transport—SLC2A4—polycystic ovary syndrome	0.00014	0.00262	CbGpPWpGaD
Famotidine—SLC22A2—Transmembrane transport of small molecules—SCNN1A—polycystic ovary syndrome	0.00014	0.00261	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—ADRA1D—polycystic ovary syndrome	0.000138	0.00257	CbGpPWpGaD
Famotidine—HRH2—Class A/1 (Rhodopsin-like receptors)—ADRB2—polycystic ovary syndrome	0.000135	0.00252	CbGpPWpGaD
Famotidine—CYP2C19—Phase 1 - Functionalization of compounds—CYP19A1—polycystic ovary syndrome	0.000135	0.00252	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—PDE3B—polycystic ovary syndrome	0.000134	0.00251	CbGpPWpGaD
Famotidine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP1A1—polycystic ovary syndrome	0.000134	0.0025	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—ADRA1B—polycystic ovary syndrome	0.000134	0.0025	CbGpPWpGaD
Famotidine—CYP2C19—Oxidation by Cytochrome P450—CYP1A1—polycystic ovary syndrome	0.000132	0.00247	CbGpPWpGaD
Famotidine—SLC22A2—Transmission across Chemical Synapses—DLG4—polycystic ovary syndrome	0.000128	0.0024	CbGpPWpGaD
Famotidine—SLC47A1—Transmembrane transport of small molecules—GNAS—polycystic ovary syndrome	0.000127	0.00237	CbGpPWpGaD
Famotidine—HRH2—GPCR ligand binding—GHRL—polycystic ovary syndrome	0.000124	0.00232	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—FLT4—polycystic ovary syndrome	0.000123	0.00229	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—FSHR—polycystic ovary syndrome	0.000122	0.00228	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—PDE3B—polycystic ovary syndrome	0.000122	0.00228	CbGpPWpGaD
Famotidine—CYP2C19—Metapathway biotransformation—AKR1C1—polycystic ovary syndrome	0.000118	0.0022	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—ADRA1A—polycystic ovary syndrome	0.000112	0.00209	CbGpPWpGaD
Famotidine—SLC22A2—Neuronal System—CAMK2D—polycystic ovary syndrome	0.000111	0.00208	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—FSHR—polycystic ovary syndrome	0.000111	0.00207	CbGpPWpGaD
Famotidine—CYP2C19—Biological oxidations—SULT2A1—polycystic ovary syndrome	0.00011	0.00205	CbGpPWpGaD
Famotidine—CYP2C19—Phase 1 - Functionalization of compounds—CYP1A1—polycystic ovary syndrome	0.000108	0.00203	CbGpPWpGaD
Famotidine—CYP2C19—Metapathway biotransformation—SULT2A1—polycystic ovary syndrome	0.000108	0.00202	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—ADRB3—polycystic ovary syndrome	0.000107	0.00201	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—NPB—polycystic ovary syndrome	0.000107	0.002	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—LHB—polycystic ovary syndrome	0.000106	0.00199	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—LPCAT2—polycystic ovary syndrome	0.000104	0.00195	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—GNRH1—polycystic ovary syndrome	0.000104	0.00194	CbGpPWpGaD
Famotidine—HRH2—GPCR ligand binding—ADRB2—polycystic ovary syndrome	0.000103	0.00192	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—ADRA1A—polycystic ovary syndrome	0.000101	0.0019	CbGpPWpGaD
Famotidine—CYP2C19—Cytochrome P450 - arranged by substrate type—POMC—polycystic ovary syndrome	9.98e-05	0.00187	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—SCT—polycystic ovary syndrome	9.95e-05	0.00186	CbGpPWpGaD
Famotidine—SLC22A2—Neuronal System—DLG4—polycystic ovary syndrome	9.85e-05	0.00184	CbGpPWpGaD
Famotidine—SLC22A2—SLC-mediated transmembrane transport—SLC2A4—polycystic ovary syndrome	9.76e-05	0.00182	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—ADRB3—polycystic ovary syndrome	9.76e-05	0.00182	CbGpPWpGaD
Famotidine—CYP2C19—Biological oxidations—CYP11A1—polycystic ovary syndrome	9.72e-05	0.00182	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—PLEKHG5—polycystic ovary syndrome	9.69e-05	0.00181	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—LHB—polycystic ovary syndrome	9.64e-05	0.0018	CbGpPWpGaD
Famotidine—CYP2C19—Metapathway biotransformation—CYP11A1—polycystic ovary syndrome	9.58e-05	0.00179	CbGpPWpGaD
Famotidine—HRH2—GPCR ligand binding—GNAS—polycystic ovary syndrome	9.52e-05	0.00178	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—MTNR1B—polycystic ovary syndrome	9.49e-05	0.00177	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—GNRH1—polycystic ovary syndrome	9.42e-05	0.00176	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—NMNAT3—polycystic ovary syndrome	9.06e-05	0.00169	CbGpPWpGaD
Famotidine—CYP2C19—Metapathway biotransformation—AKR1C3—polycystic ovary syndrome	9.05e-05	0.00169	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—SCT—polycystic ovary syndrome	9.04e-05	0.00169	CbGpPWpGaD
Famotidine—CYP2C19—Biological oxidations—CYP17A1—polycystic ovary syndrome	9.03e-05	0.00169	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—LHCGR—polycystic ovary syndrome	8.95e-05	0.00167	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—PTGER3—polycystic ovary syndrome	8.95e-05	0.00167	CbGpPWpGaD
Famotidine—CYP2C19—Metapathway biotransformation—CYP17A1—polycystic ovary syndrome	8.91e-05	0.00167	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—MTNR1B—polycystic ovary syndrome	8.62e-05	0.00161	CbGpPWpGaD
Famotidine—HRH2—Class A/1 (Rhodopsin-like receptors)—POMC—polycystic ovary syndrome	8.42e-05	0.00157	CbGpPWpGaD
Famotidine—SLC22A8—Transmembrane transport of small molecules—TFRC—polycystic ovary syndrome	8.38e-05	0.00157	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—PTAFR—polycystic ovary syndrome	8.37e-05	0.00156	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—SUOX—polycystic ovary syndrome	8.28e-05	0.00155	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—LPCAT2—polycystic ovary syndrome	8.28e-05	0.00155	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—AKR1C2—polycystic ovary syndrome	8.23e-05	0.00154	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—TEAD2—polycystic ovary syndrome	8.23e-05	0.00154	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—ADRA1D—polycystic ovary syndrome	8.12e-05	0.00152	CbGpPWpGaD
Famotidine—CYP2C19—Phase 1 - Functionalization of compounds—POMC—polycystic ovary syndrome	8.09e-05	0.00151	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—ADRA1B—polycystic ovary syndrome	7.9e-05	0.00148	CbGpPWpGaD
Famotidine—SLC22A8—Transmembrane transport of small molecules—PLAT—polycystic ovary syndrome	7.79e-05	0.00146	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—INHBB—polycystic ovary syndrome	7.7e-05	0.00144	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—ISYNA1—polycystic ovary syndrome	7.7e-05	0.00144	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—PDE3B—polycystic ovary syndrome	7.19e-05	0.00134	CbGpPWpGaD
Famotidine—CYP2C19—Biological oxidations—CYP19A1—polycystic ovary syndrome	7.15e-05	0.00134	CbGpPWpGaD
Famotidine—SLC22A8—Transmembrane transport of small molecules—SLC2A4—polycystic ovary syndrome	7.13e-05	0.00133	CbGpPWpGaD
Famotidine—CYP2C19—Metapathway biotransformation—CYP19A1—polycystic ovary syndrome	7.05e-05	0.00132	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—GHRL—polycystic ovary syndrome	7.01e-05	0.00131	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—PNPLA2—polycystic ovary syndrome	6.9e-05	0.00129	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—FSHR—polycystic ovary syndrome	6.55e-05	0.00122	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—TEAD2—polycystic ovary syndrome	6.55e-05	0.00122	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—AKR1C2—polycystic ovary syndrome	6.55e-05	0.00122	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—SRD5A1—polycystic ovary syndrome	6.54e-05	0.00122	CbGpPWpGaD
Famotidine—HRH2—GPCR ligand binding—POMC—polycystic ovary syndrome	6.41e-05	0.0012	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—GHRL—polycystic ovary syndrome	6.37e-05	0.00119	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—STAR—polycystic ovary syndrome	6.24e-05	0.00117	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—RACGAP1—polycystic ovary syndrome	6.16e-05	0.00115	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—ADRA1A—polycystic ovary syndrome	5.99e-05	0.00112	CbGpPWpGaD
Famotidine—SLC22A8—Transmembrane transport of small molecules—GNAS—polycystic ovary syndrome	5.98e-05	0.00112	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—FST—polycystic ovary syndrome	5.84e-05	0.00109	CbGpPWpGaD
Famotidine—SLC22A2—Transmembrane transport of small molecules—TFRC—polycystic ovary syndrome	5.83e-05	0.00109	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	5.8e-05	0.00108	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—ADRB3—polycystic ovary syndrome	5.76e-05	0.00108	CbGpPWpGaD
Famotidine—CYP2C19—Biological oxidations—CYP1A1—polycystic ovary syndrome	5.76e-05	0.00108	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—LHB—polycystic ovary syndrome	5.7e-05	0.00106	CbGpPWpGaD
Famotidine—CYP2C19—Metapathway biotransformation—CYP1A1—polycystic ovary syndrome	5.68e-05	0.00106	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—GNRH1—polycystic ovary syndrome	5.57e-05	0.00104	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—PNPLA2—polycystic ovary syndrome	5.49e-05	0.00103	CbGpPWpGaD
Famotidine—SLC22A2—Transmembrane transport of small molecules—PLAT—polycystic ovary syndrome	5.42e-05	0.00101	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—AKR1C1—polycystic ovary syndrome	5.39e-05	0.00101	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—GNAS—polycystic ovary syndrome	5.38e-05	0.00101	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—SCT—polycystic ovary syndrome	5.34e-05	0.000998	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—HSD3B1—polycystic ovary syndrome	5.3e-05	0.000991	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—ADRB2—polycystic ovary syndrome	5.27e-05	0.000985	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—SRD5A1—polycystic ovary syndrome	5.2e-05	0.000972	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—MTNR1B—polycystic ovary syndrome	5.09e-05	0.000952	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—NMNAT3—polycystic ovary syndrome	5.07e-05	0.000948	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—FGF18—polycystic ovary syndrome	5e-05	0.000936	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—RBP4—polycystic ovary syndrome	4.96e-05	0.000928	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—STAR—polycystic ovary syndrome	4.96e-05	0.000928	CbGpPWpGaD
Famotidine—SLC22A2—Transmembrane transport of small molecules—SLC2A4—polycystic ovary syndrome	4.96e-05	0.000927	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—GNAS—polycystic ovary syndrome	4.89e-05	0.000914	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—LHB—polycystic ovary syndrome	4.84e-05	0.000904	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—HSD3B2—polycystic ovary syndrome	4.73e-05	0.000884	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—SUOX—polycystic ovary syndrome	4.64e-05	0.000867	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—LPCAT2—polycystic ovary syndrome	4.64e-05	0.000867	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—YAP1—polycystic ovary syndrome	4.63e-05	0.000866	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—AKR1C1—polycystic ovary syndrome	4.58e-05	0.000856	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—GAB1—polycystic ovary syndrome	4.57e-05	0.000854	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—HMMR—polycystic ovary syndrome	4.42e-05	0.000827	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—INSR—polycystic ovary syndrome	4.37e-05	0.000817	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—ISYNA1—polycystic ovary syndrome	4.31e-05	0.000806	CbGpPWpGaD
Famotidine—CYP2C19—Biological oxidations—POMC—polycystic ovary syndrome	4.3e-05	0.000803	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—HSD3B1—polycystic ovary syndrome	4.22e-05	0.000789	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—SULT2A1—polycystic ovary syndrome	4.21e-05	0.000788	CbGpPWpGaD
Famotidine—SLC22A2—Transmembrane transport of small molecules—GNAS—polycystic ovary syndrome	4.16e-05	0.000778	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—AKR1C3—polycystic ovary syndrome	4.15e-05	0.000776	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—TNRC6B—polycystic ovary syndrome	4.09e-05	0.000764	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—PGR—polycystic ovary syndrome	4.05e-05	0.000756	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—YAP1—polycystic ovary syndrome	3.93e-05	0.000735	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—LHB—polycystic ovary syndrome	3.85e-05	0.000719	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—GHRL—polycystic ovary syndrome	3.76e-05	0.000703	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—PLAT—polycystic ovary syndrome	3.76e-05	0.000703	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—HSD3B2—polycystic ovary syndrome	3.76e-05	0.000703	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—CYP11A1—polycystic ovary syndrome	3.73e-05	0.000698	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—AKR1C2—polycystic ovary syndrome	3.66e-05	0.000685	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—TEAD2—polycystic ovary syndrome	3.66e-05	0.000685	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—AKR1C1—polycystic ovary syndrome	3.64e-05	0.000681	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—POMC—polycystic ovary syndrome	3.62e-05	0.000677	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—ATF1—polycystic ovary syndrome	3.59e-05	0.000671	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—AKR1C3—polycystic ovary syndrome	3.52e-05	0.000659	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—TCF7L2—polycystic ovary syndrome	3.5e-05	0.000654	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—AKT2—polycystic ovary syndrome	3.48e-05	0.000651	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—CYP17A1—polycystic ovary syndrome	3.47e-05	0.000649	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—SULT2A1—polycystic ovary syndrome	3.35e-05	0.000627	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—NGFR—polycystic ovary syndrome	3.31e-05	0.000619	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—POMC—polycystic ovary syndrome	3.29e-05	0.000615	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—PRL—polycystic ovary syndrome	3.28e-05	0.000613	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—RRM2—polycystic ovary syndrome	3.25e-05	0.000607	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—AKT2—polycystic ovary syndrome	3.16e-05	0.000591	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—YAP1—polycystic ovary syndrome	3.13e-05	0.000585	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—ADRB2—polycystic ovary syndrome	3.11e-05	0.000582	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—PNPLA2—polycystic ovary syndrome	3.07e-05	0.000574	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—NAMPT—polycystic ovary syndrome	3.01e-05	0.000562	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—CYP11A1—polycystic ovary syndrome	2.97e-05	0.000555	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—SRD5A1—polycystic ovary syndrome	2.91e-05	0.000544	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—GNAS—polycystic ovary syndrome	2.89e-05	0.00054	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—AKR1C3—polycystic ovary syndrome	2.8e-05	0.000524	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—STAR—polycystic ovary syndrome	2.78e-05	0.000519	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—CYP17A1—polycystic ovary syndrome	2.76e-05	0.000516	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—NCOR1—polycystic ovary syndrome	2.75e-05	0.000514	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—polycystic ovary syndrome	2.75e-05	0.000513	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—NRG1—polycystic ovary syndrome	2.7e-05	0.000505	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—HMMR—polycystic ovary syndrome	2.48e-05	0.000463	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—TH—polycystic ovary syndrome	2.39e-05	0.000447	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—HSD3B1—polycystic ovary syndrome	2.36e-05	0.000442	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	2.33e-05	0.000436	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—SLC2A4—polycystic ovary syndrome	2.32e-05	0.000434	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—IRS2—polycystic ovary syndrome	2.31e-05	0.000432	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—LEP—polycystic ovary syndrome	2.26e-05	0.000423	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	2.21e-05	0.000414	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—CYP19A1—polycystic ovary syndrome	2.18e-05	0.000408	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—LHB—polycystic ovary syndrome	2.15e-05	0.000403	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—HSD3B2—polycystic ovary syndrome	2.1e-05	0.000394	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—AKR1C1—polycystic ovary syndrome	2.04e-05	0.000381	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—IRS1—polycystic ovary syndrome	2.02e-05	0.000377	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—GNAS—polycystic ovary syndrome	1.95e-05	0.000365	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—POMC—polycystic ovary syndrome	1.94e-05	0.000363	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—INS—polycystic ovary syndrome	1.93e-05	0.000361	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—SULT2A1—polycystic ovary syndrome	1.88e-05	0.000351	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—IGF1—polycystic ovary syndrome	1.87e-05	0.00035	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—AKT2—polycystic ovary syndrome	1.87e-05	0.000349	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—NCOR1—polycystic ovary syndrome	1.86e-05	0.000347	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—RRM2—polycystic ovary syndrome	1.82e-05	0.00034	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.78e-05	0.000332	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—CYP1A1—polycystic ovary syndrome	1.76e-05	0.000329	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—YAP1—polycystic ovary syndrome	1.75e-05	0.000327	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—NAMPT—polycystic ovary syndrome	1.68e-05	0.000315	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	1.67e-05	0.000313	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—CYP11A1—polycystic ovary syndrome	1.66e-05	0.000311	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	1.65e-05	0.000308	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—MTHFR—polycystic ovary syndrome	1.64e-05	0.000307	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—AKR1C3—polycystic ovary syndrome	1.57e-05	0.000293	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—CYP17A1—polycystic ovary syndrome	1.54e-05	0.000289	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—IL6—polycystic ovary syndrome	1.43e-05	0.000267	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—TH—polycystic ovary syndrome	1.34e-05	0.00025	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—PPARG—polycystic ovary syndrome	1.33e-05	0.000249	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—POMC—polycystic ovary syndrome	1.31e-05	0.000245	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—INS—polycystic ovary syndrome	1.31e-05	0.000244	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—SLC2A4—polycystic ovary syndrome	1.3e-05	0.000243	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—CYP19A1—polycystic ovary syndrome	1.22e-05	0.000229	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.22e-05	0.000228	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—GNAS—polycystic ovary syndrome	1.09e-05	0.000204	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—NCOR1—polycystic ovary syndrome	1.04e-05	0.000194	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—CYP1A1—polycystic ovary syndrome	9.85e-06	0.000184	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—MTHFR—polycystic ovary syndrome	9.19e-06	0.000172	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—IL6—polycystic ovary syndrome	8.45e-06	0.000158	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—PPARG—polycystic ovary syndrome	7.45e-06	0.000139	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—POMC—polycystic ovary syndrome	7.35e-06	0.000137	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—INS—polycystic ovary syndrome	7.31e-06	0.000137	CbGpPWpGaD
